8-K: TuHURA Biosciences Faces Nasdaq Delisting Warning

TuHURA Biosciences, Inc. received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day grace period to regain compliance.

Summary

• TuHURA Biosciences, Inc. (HURA) received a notice from The Nasdaq Stock Market LLC on January 29, 2026, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2).
• The non-compliance stems from the company's consolidated closing bid price being below $1.00 per share for 35 consecutive business days as of January 28, 2026.
• The company has been granted an automatic 180-calendar day grace period, until July 28, 2026, to regain compliance.
• To regain compliance, the common stock's closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days during this grace period.
• A second 180-day grace period may be afforded if the company meets other listing standards and intends to cure the deficiency, potentially through a reverse stock split.
• Failure to regain compliance could lead to delisting, unless the company requests a hearing before a Nasdaq Hearings Panel.
• The notice does not immediately affect the company's business, operations, or SEC reporting requirements.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development, as a delisting notice from Nasdaq indicates severe market underperformance and poses a material risk to the company's public trading status and investor confidence.

Positives

• The notice does not result in the immediate delisting of the company's common stock.
• The company has been automatically afforded a 180-calendar day grace period to regain compliance.
• A second 180-day grace period may be available under certain conditions.

Negatives

• The company is not in compliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock trading below $1.00 per share for 35 consecutive business days.
• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement.
• Failure to regain compliance could lead to the delisting of the company's common stock from The Nasdaq Capital Market.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the minimum bid price requirement.
• Uncertainty regarding the company's ability to regain compliance with the minimum bid price requirement or other Nasdaq listing criteria.
• General risks and uncertainties that could cause actual results to differ materially from forward-looking statements, as detailed in the company's SEC filings.

Future Outlook

The company intends to monitor the closing bid price of its common stock and consider its available options to resolve the non-compliance with the minimum bid price requirement. There is no assurance that the company will be able to regain compliance.

Management Comments

• "The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options to resolve the non-compliance with the minimum bid price requirement."
• "The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law."

Industry Context

StockSavvy.ai notes that a Nasdaq delisting notice for a biotech company like TuHURA Biosciences often signals underlying challenges, such as a lack of significant clinical progress, market skepticism regarding its pipeline, or broader financial instability. Maintaining Nasdaq listing is crucial for investor confidence and access to capital, especially for development-stage companies in the capital-intensive biotech sector.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, potential loss of liquidity, and further erosion of share value. The possibility of a reverse stock split could also impact share structure.
• Investors: May lose confidence in the company's ability to maintain its listing and attract capital, potentially leading to divestment.

Next Steps

• Monitor the closing bid price of the common stock.
• Consider available options to resolve the non-compliance with the minimum bid price requirement.
• Potentially effect a reverse stock split if a second compliance period is pursued.
• Request a hearing before a Nasdaq Hearings Panel if compliance is not regained and a second period is not granted.

Key Dates

Recommendation

The Nasdaq delisting notice is a critical negative event, signaling severe underperformance and significant risk to the company's market access and investor confidence. While a grace period exists, the underlying issues causing the low bid price are likely substantial. Seasoned investors would view this as a strong indicator to exit positions due to the high probability of further share price decline, potential delisting, and the uncertainty surrounding the company's ability to regain compliance.

Keywords

TuHURA Biosciences, HURA, Nasdaq, delisting, minimum bid price, compliance, biotech, stock market, reverse stock split, SEC filing